Bridgeway Capital Management LLC Cuts Holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Bridgeway Capital Management LLC reduced its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 59.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 72,600 shares of the company’s stock after selling 108,477 shares during the quarter. Bridgeway Capital Management LLC owned about 0.24% of Relmada Therapeutics worth $38,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. AdvisorShares Investments LLC raised its position in shares of Relmada Therapeutics by 206.5% in the 4th quarter. AdvisorShares Investments LLC now owns 210,068 shares of the company’s stock worth $109,000 after buying an additional 141,540 shares during the period. Renaissance Technologies LLC raised its position in shares of Relmada Therapeutics by 535.5% in the 4th quarter. Renaissance Technologies LLC now owns 164,513 shares of the company’s stock worth $86,000 after buying an additional 138,625 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Relmada Therapeutics by 28.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,302,151 shares of the company’s stock worth $4,362,000 after buying an additional 289,490 shares during the period. 45.24% of the stock is owned by hedge funds and other institutional investors.

Relmada Therapeutics Trading Down 2.1%

Shares of RLMD opened at $0.39 on Wednesday. The firm has a market capitalization of $12.94 million, a P/E ratio of -0.14 and a beta of 0.18. The stock’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.88. Relmada Therapeutics, Inc. has a twelve month low of $0.24 and a twelve month high of $4.47.

Relmada Therapeutics (NASDAQ:RLMD) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.27). Sell-side analysts predict that Relmada Therapeutics, Inc. will post -2.73 earnings per share for the current year.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.